The independent source for health policy research, polling, and news.
261-280 of 1,313 results
Supporters say the proposed rules would balance the goals of increasing access to health care and helping prevent medication misuse. Opponents say the rules would make it difficult for some patients — especially those in rural areas — to get care.
A quality-control crisis at an Indian pharmaceutical factory has left doctors and their patients with impossible choices as cheap, effective, generic cancer drugs go out of stock.
The views of the leader of a broad anti-vaccine movement who is now running for president are unchallenged in public forums run by several prominent Silicon Valley figures.
The bipartisan deal to extend the U.S. government’s borrowing authority includes future cuts to federal health agencies, but they are smaller than many expected and do not touch Medicare and Medicaid. Meanwhile, Merck & Co. becomes the first drugmaker to sue Medicare officials over the federal health insurance program’s new authority to negotiate drug prices. Joanne Kenen of the Johns Hopkins Bloomberg School of Public Health and Politico, Lauren Weber of The Washington Post, and Jessie Hellmann of CQ Roll Call join 51ĘÓƵ Health News’ chief Washington correspondent, Julie Rovner, to discuss these issues and more. Also this week, Rovner interviews 51ĘÓƵ Health News senior correspondent Sarah Jane Tribble, who reported the latest 51ĘÓƵ Health News-NPR “Bill of the Month” feature, about the perils of visiting the U.S. with European health insurance.
The “Diabetes Belt,” as defined by the Centers for Disease Control and Prevention, comprises 644 mostly Southern counties where diabetes rates are high. Of those counties, 51ĘÓƵ Health News and NPR found, more than half also have high levels of medical debt.
Robert F. Kennedy Jr.’s official entry into the presidential race poses a thorny challenge for journalists: how to cover a candidate who’s opposed to vaccines without amplifying misinformation. And South Carolina becomes the latest state in the South to ban abortion after roughly six weeks of pregnancy. Alice Miranda Ollstein of Politico, Rachel Cohrs of Stat, and Sarah Karlin-Smith of the Pink Sheet join 51ĘÓƵ Health News chief Washington correspondent Julie Rovner to discuss these issues and more. Also this week, Rovner interviews 51ĘÓƵ Health News senior correspondent Aneri Pattani about her project to track the billions of dollars coming from opioid makers to settle lawsuits.
Colorado’s new Prescription Drug Affordability Board could cap what health plans and consumers pay for certain medications starting next year. The process will pit patient groups against one another.
Industry analysts are skeptical that Federal Trade Commission Chair Lina Khan can win her first fight against a drug industry merger. It will be reviewed by a judge appointed by then-President Donald Trump.
Sen. Bernie Sanders’ broad statement that some U.S. drug prices are 10 times those of other nations doesn’t paint the full picture. Studies we examined generally found that U.S. prices were two to four times those in other countries, not 10.
Greene County, Tennessee, so far has received more than $2.7 million from regional and national settlements with opioid manufacturers and distributors. But most of the money is not going to help people and families harmed by addiction.
The public health emergency declaration for covid-19 ends May 11, ushering in major changes in how Americans can access and pay for the vaccines, treatments, and tests particular to the culprit coronavirus. But not everyone will experience the same changes, creating a confusing patchwork of coverage — not unlike health coverage for other diseases. Meanwhile, outside advisers to the FDA formally recommended allowing a birth control pill to be sold without a prescription. If the FDA follows the recommendation, it would represent the first over-the-counter form of hormonal contraception. Margot Sanger-Katz of The New York Times, Tami Luhby of CNN, and Joanne Kenen of the Johns Hopkins Bloomberg School of Public Health and Politico join 51ĘÓƵ Health News’ Julie Rovner to discuss these issues and more. Plus for “extra credit” the panelists suggest health policy stories they read this week they think you should read, too.
Drugmakers, pharmacies, and physicians blame pharmacy benefit managers for high drug prices. Congress is finally on board, too, but will it matter?
Individuals newly released from prison are 40 times as likely to die of opioid overdoses than members of the general population, researchers say. In response, California corrections officials aim to arm departing inmates with an antidote that can be used to reverse the effects of opioid poisoning.
The controversial practice of administering progesterone to people after they have taken the abortion pill mifepristone may be coming to an end in Colorado. Pills have emerged as the latest front in the war over abortion since the U.S. Supreme Court overturned Roe v. Wade last summer.
51ĘÓƵ Health News senior correspondent Aneri Pattani appeared on NPR’s “1A” on May 1 to discuss issues related to how opioid settlement funds are being distributed.
The Supreme Court on April 21 ruled that the abortion pill mifepristone should remain widely available while the lower courts consider the issue, blocking earlier rulings that banned or restricted access to the drug. 51ĘÓƵ Health News’ Julie Rovner joined NPR’s “Weekend All Things Considered” to discuss the complicated case.
A group of former professional athletes traveled to Jamaica to try psychedelics as a way to help cope with the aftereffects of concussions and a career of body-pounding injuries. Will this still largely untested treatment work?
Billions of dollars are headed to state and local governments to address the opioid crisis. Policy experts and advocates expect the federal government to play a role in overseeing the use of the money. Failure to do so, they say, could lead to wasted opportunities. And, since Medicaid helps pay health care costs, the feds could have a claim to portions of states’ opioid settlements.
The Supreme Court is considering the future of the abortion pill mifepristone, after GenBioPro sued the FDA over limitations that effectively block generic production of the drug, a major part of the market. Congress is considering proposals that would impose Medicaid work requirements, crack down on pharmacy benefit managers, and more. And President Joe Biden moved to expand health coverage to young immigrants known as “Dreamers.” Rachel Cohrs of Stat, Sandhya Raman of CQ Roll Call, and Joanne Kenen of the Johns Hopkins Bloomberg School of Public Health and Politico join 51ĘÓƵ Health News’ Mary Agnes Carey to discuss these issues and more.
Online platforms are overflowing with testimonials for GLP-1s. The drugs show promise for inducing weight loss, but many aren’t FDA-approved for that use.
© 2026 51ĘÓƵ